Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:5494-5494.

Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma

Akihiro Ohmoto, Masami Suzuki, Erina Takai, Hirofumi Rokutan, Yuko Fujiwara, Chigusa Morizane, Kazuyoshi Yanagihara, Tatsuhiro Shibata and Shinichi Yachida _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:21086-21099. https://doi.org/10.18632/oncotarget.24930

Metrics: PDF 576 views  |   HTML 1142 views  |   ?  


Abstract

Akihiro Ohmoto1, Masami Suzuki1, Erina Takai1, Hirofumi Rokutan2, Yuko Fujiwara1, Chigusa Morizane3, Kazuyoshi Yanagihara4, Tatsuhiro Shibata2,5 and Shinichi Yachida1,6

1Laboratory of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan

2Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan

3Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

4Division of Biomarker Discovery, Exploratory Oncology and Clinical Trial Center, National Cancer Center, Chiba, Japan

5Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

6Department of Cancer Genome Informatics, Graduate School of Medicine/Faculty of Medicine, Osaka University, Osaka, Japan

Correspondence to:

Shinichi Yachida, email: syachida@cgi.med.osaka-u.ac.jp

Keywords: cell line; cisplatin; etoposide; irinotecan; neuroendocrine carcinoma

Received: November 27, 2017     Accepted: February 27, 2018     Published: April 20, 2018

ABSTRACT

Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a rare and devastating malignancy, and preclinical studies are needed to evaluate potential therapeutic regimens. Here, we examined the antitumor effects of cisplatin (CDDP), etoposide (ETP) and irinotecan (CPT-11) and their combinations on GEP-NEC using three small-cell GEP-NEC cell lines (pancreatic NEC, A99; esophageal NEC, TYUC-1; duodenum NEC, TCC-NECT-2). In vitro studies were conducted using cell viability assays. In vivo experiments were conducted in mice inoculated with A99 or TCC-NECT-2 and treated with no agent, CDDP, CDDP+ETP (EP) or CDDP+CPT-11 (IP). TYUC-1 was the most susceptible to all agents, whereas A99 was refractory. Classical isobolograms showed synergism in both the EP and IP combinations for the three cell lines. In the TCC-NECT-2 mouse model, the IP regimen showed a significant antitumor effect, and CDDP alone showed a marginal effect compared to the control. In contrast, no effect was detected in the A99 model, probably because A99 was established from a metastatic tumor after chemotherapy with EP. Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines. These preclinical models indicate that CDDP is a key agent, and IP regimen might be a reasonable option, although its efficacy is moderate. Our data on the platinum-based regimen will be useful as reference information in developing new agents for GEP-NEC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24930